Qube Research & Technologies (QRT)
VRTX icon

Qube Research & Technologies (QRT)’s Vertex Pharmaceuticals VRTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Sell
3,000
-7,200
-71% -$3.19M ﹤0.01% 2254
2026
Q1 		$4.55M Sell
10,200
-15,900
-61% -$7.41M 0.01% 1712
2025
Q4 		$11.8M Buy
26,100
+9,000
+53% +$3.88M 0.01% 1234
2025
Q3 		$6.7M Sell
17,100
-3,500
-17% -$1.46M 0.01% 1567
2025
Q2 		$9.17M Buy
20,600
+10,500
+104% +$4.84M 0.01% 1336
2025
Q1 		$4.9M Sell
10,100
-28,500
-74% -$13.3M 0.01% 1549
2024
Q4 		$15.5M Sell
38,600
-191,700
-83% -$88.9M 0.02% 836
2024
Q3 		$107M Buy
230,300
+79,500
+53% +$38.2M 0.16% 135
2024
Q2 		$70.7M Buy
+150,800
New +$65.5M 0.11% 205
2024
Q1 		– Sell
-26,000
Closed -$10.6M – 4906
2023
Q4 		$10.6M Sell
26,000
-8,600
-25% -$3.18M 0.02% 712
2023
Q3 		$12M Buy
+34,600
New +$12.1M 0.03% 570

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Qube Research & Technologies (QRT)'s VRTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 3,998 shares — an estimated $1.77M sold.

Qube Research & Technologies (QRT) first reported a position in VRTX in Q1 2018 and held it in 22 quarters. The position peaked at $233M in Q1 2024. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 3,998 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.77M.
  • Qube Research & Technologies (QRT) first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 22 quarters.
  • Qube Research & Technologies (QRT)'s Vertex Pharmaceuticals position peaked at $233M in Q1 2024.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.